Two new drugs for advanced lung cancer without EGFR or ALK
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two new drugs, SKB264 and SKB118, for people with advanced non-small cell lung cancer. It may be an option if your cancer does not have the EGFR or ALK gene changes and you are in relatively good health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your lung cancer must be advanced (spread to nearby tissues or other parts of the body) and cannot be a type called small cell.
- You must not have certain gene changes called EGFR or ALK in your cancer.
- You need to be willing to provide a small piece of tumor tissue for testing.
- You should be able to do most of your daily activities (ECOG score 0 or 1) and have a life expectancy of at least 3 months.
- Your blood, liver, kidney, and clotting function must be working well enough as determined by blood tests.
- If you are able to have children, you must agree to use effective birth control during the study and for a period after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (SKB264 and glecirasib) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests two new drugs—SHR-A1921 and adebrelimab—for people with advanced non-small cell lung cancer (NSCLC) whose cancer has grown after standard first-line treatment. The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a combination of two new drugs (SKB264 and SKB118) for people with a specific type of lung cancer (non-squamous non-small cell) that has an EGFR mutation and has stopped responding to standard EGFR inhibitor treatment. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a new combination of two medications (SKB264 and anlotinib) for people with advanced non-small cell lung cancer that has spread to the liver and no longer responds to a standard pill called an EGFR-TKI. The goal is to see if this combination can shrink tumors and help people live longer.
This Phase 2 trial tests a combination treatment to control advanced or metastatic non-small cell lung cancer (NSCLC). It is mainly for people whose tumor has specific gene features (EGFR and ALK testing results) and who are able to provide tumor tissue for biomarker testing.
This trial tests a new drug called SKB571 in people with advanced non-small cell lung cancer. The goal is to see if it can help shrink tumors or slow cancer growth.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.